Biotech Shares Catch Premarket Bid On Tuesday
March 21 2023 - 10:15AM
AllPennyStocks.com
A Massachusetts-based biotech company is
finding early success on Tuesday after the company announced the
Phase 3 DISSOLVE program of their SEL-212 in chronic refractory
gout met...
To read the full story on AllPennyStocks.com, click
here.
Selecta Biosciences (NASDAQ:SELB)
Historical Stock Chart
From Dec 2024 to Jan 2025
Selecta Biosciences (NASDAQ:SELB)
Historical Stock Chart
From Jan 2024 to Jan 2025